Qiu, Jingya
Xu, Bihui
Ye, Darwin
Ren, Diqiu
Wang, Shangshang
Benci, Joseph L.
Xu, Yuanming
Ishwaran, Hemant
Beltra, Jean-Christophe
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Shi, Junwei http://orcid.org/0000-0002-8427-6316
Minn, Andy J. http://orcid.org/0000-0003-1418-0906
Funding for this research was provided by:
Mark Foundation for Cancer Research (19-011MIA); Parker Institute for Cancer Immunotherapy
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1-P01-CA-210944-01, 1-P01-CA-210944-01, 1-P01-CA-210944-01, 1-P01-CA-210944-01)
Breast Cancer Research Foundation
Parker Institute for Cancer Immunotherapy
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5T32HG000046-18)
Mark Foundation for Cancer Research (19-011MIA); Parker Institute for Cancer Immunotherapy; Breast Cancer Research Foundation
Article History
Received: 8 April 2020
Accepted: 10 November 2022
First Online: 16 January 2023
Competing interests
: A.J.M. is a project member of the Parker Institute for Cancer Immunotherapy and has received research funding from Merck. He has also received honoraria and travel support from Merck, AstraZeneca and Pfizer. He is a scientific founder for Dispatch Biotherapeutics and a scientific consultant for Takeda, Xilio, H3 Biomedicine and Related Sciences. A.J.M. is an inventor on patents related to the IFN pathway and is on a filed patent related to modified CAR T cells. J.L.B. is currently an employee of Bristol Myers Squibb. Y.X. is a current employee of Pfizer. B.X. is currently an employee of Incyte. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy and has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar and Surface Oncology. E.J.W. has a patent licensing agreement on the PD1 pathway with Roche–Genentech and is a founder of Arsenal Biosciences. The remaining authors declare no relevant competing interests.